CIK 0001813814 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Definium Therapeutics, Inc.
Sign in to watch- Ticker
- DFTX
- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- 212-220-6633
- Business address
- ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK, NY, 10007
- Former names
- Mind Medicine (MindMed) Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,023,010
- in 6 filings, $3.0M under 10b5-1 plans
Net −$3,023,010. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Barrow Robert −$1.9M Chief Executive Officer sold 2% of stake
- Sullivan Mark −$514K Chief Legal Officer sold 3% of stake
- Karlin Daniel −$397K Chief Medical Officer sold 1% of stake
- Roberts Brandi −$123K Chief Financial Officer sold <1% of stake
- Wiley Matthew T. −$113K Chief Commercial Officer sold <1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-12 | Roberts Brandi Chief Financial Officer | Grant or award | +62,500 | 271,987 | ||
| 2026-06-25 | Sullivan Mark Chief Legal Officer | Sale 10b5-1 | −13,008 | $45.03 | $586K | 320,571 |
| 2026-06-25 | Karlin Daniel Chief Medical Officer | Sale 10b5-1 | −10,035 | $45.03 | $452K | 503,282 |
| 2026-06-25 | Roberts Brandi Chief Financial Officer | Sale 10b5-1 | −3,013 | $45.03 | $136K | 209,487 |
| 2026-06-25 | Barrow Robert Chief Executive Officer | Sale 10b5-1 | −29,208 | $45.03 | $1.3M | 1,098,246 |
| 2026-06-25 | Wiley Matthew T. Chief Commercial Officer | Sale 10b5-1 | −2,867 | $45.03 | $129K | 174,633 |
| 2026-06-22 | Barrow Robert Chief Executive Officer | Grant or award | +375,000 | 1,127,454 | ||
| 2026-06-22 | Wiley Matthew T. Chief Commercial Officer | Grant or award | +62,500 | 177,500 | ||
| 2026-06-22 | Roberts Brandi Chief Financial Officer | Grant or award | +62,500 | 212,500 | ||
| 2026-06-22 | Sullivan Mark Chief Legal Officer | Grant or award | +62,500 | 333,579 | ||
| 2026-06-22 | Karlin Daniel Chief Medical Officer | Grant or award | +100,000 | 513,317 | ||
| 2026-06-11 | CRYSTAL ROGER Director | Grant or award | +4,666 | 24,289 | ||
| 2026-06-11 | CRYSTAL ROGER Director | Grant or award · Stock Option (Right to Buy) | +19,188 | 19,188 | ||
| 2026-06-11 | GRYSKA DAVID W Director | Grant or award | +4,666 | 19,900 | ||
| 2026-06-11 | GRYSKA DAVID W Director | Grant or award · Stock Option (Right to Buy) | +19,188 | 19,188 | ||
| 2026-06-11 | Vallone Carol A Director | Grant or award | +4,666 | 21,210 | ||
| 2026-06-11 | Vallone Carol A Director | Grant or award · Stock Option (Right to Buy) | +19,188 | 19,188 | ||
| 2026-06-11 | Krebs Andreas Director | Grant or award | +4,666 | 19,773 | ||
| 2026-06-11 | Krebs Andreas Director | Grant or award · Stock Option (Right to Buy) | +19,188 | 19,188 | ||
| 2026-06-11 | Adsett Roger Director | Grant or award | +3,555 | 3,555 |
Page 2 of 12 · 225 trades